DK0557876T3 - Use of xanthine derivatives for the treatment of muscle damage after complete interruption of blood circulation - Google Patents

Use of xanthine derivatives for the treatment of muscle damage after complete interruption of blood circulation

Info

Publication number
DK0557876T3
DK0557876T3 DK93102450.9T DK93102450T DK0557876T3 DK 0557876 T3 DK0557876 T3 DK 0557876T3 DK 93102450 T DK93102450 T DK 93102450T DK 0557876 T3 DK0557876 T3 DK 0557876T3
Authority
DK
Denmark
Prior art keywords
atoms
treatment
blood circulation
radical
muscle damage
Prior art date
Application number
DK93102450.9T
Other languages
Danish (da)
Inventor
Ismahan Dr Okyayuz-Baklouti
Maurice Dr Mars
Michael Alfred Gregory
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0557876T3 publication Critical patent/DK0557876T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Xanthine derivatives of the formula I <IMAGE> where at least one of the radicals R<1> and R<3> is a radical of the formula Ia <IMAGE> R<4> is a (C1-C3)-alkyl radical, n is an integer from 2 to 5 and, if only one of the radicals R<1> and R<3> is such a tertiary hydroxyalkyl group of the formula Ia, the other radical is a hydrogen atom or an aliphatic hydrocarbon radical R<5> which has up to 6 C atoms and whose carbon chain can be interrupted by up to 2 oxygen atoms or be substituted by an oxo group or up to two hydroxyl groups, these oxo and hydroxyl groups being separated from the ring nitrogen by at least 2 C atoms, and R<2> is an alkyl group with 1-4 C atoms, are suitable for the preparation of pharmaceutical compositions for the prophylaxis and treatment of muscle damage which may occur after interruption of the blood circulation.
DK93102450.9T 1992-02-22 1993-02-17 Use of xanthine derivatives for the treatment of muscle damage after complete interruption of blood circulation DK0557876T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4205424 1992-02-22

Publications (1)

Publication Number Publication Date
DK0557876T3 true DK0557876T3 (en) 1997-05-26

Family

ID=6452327

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93102450.9T DK0557876T3 (en) 1992-02-22 1993-02-17 Use of xanthine derivatives for the treatment of muscle damage after complete interruption of blood circulation

Country Status (13)

Country Link
EP (1) EP0557876B1 (en)
JP (1) JP3193800B2 (en)
KR (1) KR930017580A (en)
AT (1) ATE146078T1 (en)
AU (1) AU658979B2 (en)
CA (1) CA2089959A1 (en)
DE (1) DE59304710D1 (en)
DK (1) DK0557876T3 (en)
ES (1) ES2096115T3 (en)
GR (1) GR3022183T3 (en)
HU (1) HUT64472A (en)
TW (1) TW288977B (en)
ZA (1) ZA931184B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3792266B2 (en) * 1994-06-16 2006-07-05 森精機興産株式会社 Method and apparatus for correcting thermal displacement of machine tool
DE19540798A1 (en) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as medicines
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
WO2007041506A1 (en) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Purine formulations and methods for managing disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH608236A5 (en) * 1974-01-22 1978-12-29 Wuelfing J A Fa
DE3525801A1 (en) * 1985-07-19 1987-01-22 Hoechst Ag TERTIA HYDROXYALKYLXANTHINE, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCT CONTAINING IT AND THEIR USE
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
ES2087205T3 (en) * 1990-11-07 1996-07-16 Hoechst Roussel Pharma USE OF XANTHINES FOR THE PREPARATION OF AN EFFECTIVE MEDICATION TO INHIBIT THE REPLICATION OF HUMAN RETROVIRUSES.

Also Published As

Publication number Publication date
TW288977B (en) 1996-10-21
KR930017580A (en) 1993-09-20
ATE146078T1 (en) 1996-12-15
AU3376193A (en) 1993-08-26
GR3022183T3 (en) 1997-03-31
HUT64472A (en) 1994-01-28
CA2089959A1 (en) 1993-08-23
JP3193800B2 (en) 2001-07-30
ES2096115T3 (en) 1997-03-01
EP0557876A1 (en) 1993-09-01
JPH069634A (en) 1994-01-18
HU9300476D0 (en) 1993-05-28
EP0557876B1 (en) 1996-12-11
ZA931184B (en) 1993-09-16
DE59304710D1 (en) 1997-01-23
AU658979B2 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
DK139287A (en) TERTIARY HYDROXYALKYLXANTHINES, THEIR PREPARATION AND USE AS MEDICINES
ES2150903T3 (en) DERIVATIVES OF 2-ARALCOXI AND 2-ALCOXI ADENOSINE USEFUL AS CORONARY VASODILATORS AND AS ANTI-HYPERTENSIVE AGENTS.
SE9100342D0 (en) NOVEL STEROID ESTERS
DK0557876T3 (en) Use of xanthine derivatives for the treatment of muscle damage after complete interruption of blood circulation
ES2041246T3 (en) PROCEDURE FOR THE RETICULATION OF ORGANOPOLISILOXANES.
ES2061959T3 (en) BENZENE DERIVATIVES SUBSTITUTED FOR FLUORINE.
DE3855902D1 (en) Manufacturing process for 2,5-diamino-6-nitro-pyridine derivatives and new 2,5-diamino-6-nitro-pyridine derivatives
DE69119700D1 (en) Use of xanthines in the manufacture of medicaments to inhibit the proliferation of human retroviruses
NZ216125A (en) Isoxazoles and pharmaceutical compositions
ES2096800T3 (en) BENZO (B) THIOFEN-3-IL-PIPERAZINES, A PROCEDURE FOR ITS PREPARATION AND USE AS MEDICINES.
ATE56944T1 (en) SUBSTITUTED 2-AMINOTETRALINES.
ATE18548T1 (en) PYRROLIDINE DERIVATIVES, PREPARATION AND MEDICINAL USE.
DK0424248T3 (en) 20,21-dinoreburnamein with substitution at the 15-position, process for their preparation and intermediates for use therewith, their use as drugs and preparations containing them
ES436233A2 (en) Derivatives of substituted tetrahydro-m-oxazines
RU93004489A (en) MEDICINE FOR PREVENTION AND TREATMENT OF DAMAGE TO MUSCLE AFTER INTERRUPTION OF CIRCULATION AND METHOD OF TREATMENT